article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize. 2] Novo Holdings $16.5

M&A
article thumbnail

Mike Khouw on a hedging strategy with the market at record highs and some threats emerging

CNBC: Investing

We are also kicking off the first earnings season, where publicly traded companies will report a full quarter's worth of operating results under the new administration.SPX 1Y mountain S & P 500 , 1 year During this period, the markets experienced historic volatility induced by policy proposals. Time to hedge?

S&P
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK Corporate Briefing - August 2025

JD Supra: Mergers

hide - hide Back to Top Home What Is JD Supra?

article thumbnail

Securities Litigation Against Life Sciences Companies 2024 Year in Review

JD Supra: Mergers

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies. By: Goodwin

article thumbnail

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

Global Newswire by Notified: M&A

SARASOTA, Fla. and AVENTURA, Fla.,

article thumbnail

Josh Mastracci joins TM Capital as Director

TM Capital

Josh Mastracci has joined TM Capital as a Director in the firm’s Healthcare practice. Josh has extensive experience completing transactions across key healthcare services sectors including physician practice management, ambulatory surgery centers, and pharmaceutical services.

article thumbnail

Behind the Buyouts: Goldman’s Dubner on Rise in Spinoffs

The Deal

While spinoffs tend to be size and industry agnostic, Dubner said a growing number of transactions have been above $5 billion, with industrials and healthcare — which tend to have more complex portfolios — accounting for 50% of globally announced transactions in 2022. Goldman has advised on major spinoffs such as Kellogg Co.’s